Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2113MR)

This product GTTS-WQ2113MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2113MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4866MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ11661MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ3153MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ526MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ13330MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ9513MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ3901MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ15194MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW